close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

55.50 -4.33 (-7.24%)
Delayed Quote Updated: 10:58 AM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup ↗
TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback ↗
TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects. 
Via Benzinga
TG Therapeutics Board Authorizes New $100M Share Repurchase Program ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What's Next: TG Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug ↗
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. 
Via Stocktwits
Topics Earnings
News headline image
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗
 
Via Benzinga
News headline image
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide ↗
TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth. 
Via Benzinga
News headline image
TG Therapeutics Q2 Revenue Up 91% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook ↗
The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche. 
Via Investor's Business Daily
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance ↗
TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook. 
Via Chartmill
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup ↗
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,... 
Via Chartmill
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template ↗
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal... 
Via Chartmill
News headline image
Cramer Backs This Mining Giant After $1.6B Bet ↗
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth. 
Via Benzinga
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup ↗
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
News headline image
TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook ↗
Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors. 
Via Stocktwits
News headline image
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show ↗
TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025. 
Via Benzinga
News headline image
Why TG Therapeutics Stock Was Tumbling Today ↗
Via The Motley Fool
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
 
Via Benzinga
News headline image
TG Therapeutics Stock Tumbles After Q1 Earnings Fall Short Of Wall Street Estimates: But Retail’s Optimistic ↗
The company, however, raised its full-year 2025 global net revenue target to approximately $575 million, up from its previous guidance of $540 million. 
Via Stocktwits
News headline image
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗
A fundamental and technical analysis of (NASDAQ:TGTX): Is TG THERAPEUTICS INC (NASDAQ:TGTX) suited for high growth investing? 
Via Chartmill
News headline image
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate ↗
TG Therapeutics Inc (NASDAQ:TGTX): A Strong Minervini Trend Template Candidate 
Via Chartmill
News headline image
Exploring high growth characteristics of TG THERAPEUTICS INC (NASDAQ:TGTX). ↗
UA fundamental and technical analysis of (NASDAQ:TGTX): nlocking the high Growth Potential of TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
News headline image
Price Over Earnings Overview: TG Therapeutics ↗
 
Via Benzinga
News headline image
Applying Mark Minervini’s growth stock checklist to TG THERAPEUTICS INC (NASDAQ:TGTX) ↗
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:TGTX). 
Via Chartmill
News headline image
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗
The companies both have drugs that treat relapsing forms of multiple sclerosis. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.